homovanillic acid has been researched along with pramipexole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, AJ; Müller, RE | 1 |
| Kitamura, Y; Kohno, Y; Nakazawa, M; Nomura, Y | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
3 other study(ies) available for homovanillic acid and pramipexole
| Article | Year |
|---|---|
Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Azepines; Benzothiazoles; Chromatography, High Pressure Liquid; Corpus Striatum; Dialysis; Dopamine; Dopamine Agents; Dopamine Antagonists; Extracellular Space; Homovanillic Acid; Male; Pramipexole; Rats; Rats, Inbred Strains; Sulpiride; Thiazoles | 1991 |
Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Azepines; Benzothiazoles; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Homovanillic Acid; In Vitro Techniques; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neostriatum; Pramipexole; Synaptosomes; Thiazoles | 1997 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |